AHA: Putting a Price on PCSK9 Inhibitor in ACS

(MedPage Today) — At $13,000 per year, alirocumab still cost-effective for patients with LDL-C 100 mg/dL

Source link

Related posts

Medication Confiscation: How Migrant Children Are Placed in Medically Vulnerable Conditions


More Frequent Family Dinners Tied to Healthier Diets in Young People


How a new father views his relationship with his partner


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy